YOLFTbeta
25

Sugentech Inc

253840 · KQ · Healthcare / Medical Devices

3,960.00KRW+60.00 (+1.54%)

Price History

Full chart

Market Stats

Previous Close3,900.00
Open3,870.00
Day Range3,845.00 – 3,970.00
52-Week Range3,530.00 – 8,250.00
Volume95.73K
Market Cap70.18B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.60
50-Day Avg4,334.60
200-Day Avg5,138.85

About

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products. The company was formerly known as Accugen Healthcare, Inc. and changed its name to Sugentech Inc. in October 2013. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMs. Jin Mi
  • Employees144
  • Headquarters206, Techno 2-ro, Daejeon, South Korea, Korea
  • Websitehttps://sugentech.com

Leadership

  • Ms. Jin MiChief Executive Officer · b. 1965
  • Mr. Hae-Kwon LeeCFO, MD & Director · b. 1970
  • Mr. Seungbeom YooChief Technology Officer · b. 1967
  • Mr. JinHyeon LimHead of Production · b. 1971
  • Ms. SooJin GooHead of Quality Management · b. 1968
  • Mr. SeHyeong JoExecutive Director · b. 1973

Financials

Income Statement

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.09B3.44B5.45B3.85B41.35B77.20B101.40B7.13B10.10B9.42B
Growth (%)-+215.52%+58.40%-29.43%+975.45%+86.69%+31.34%-92.97%+41.57%-6.74%
Cost of Revenue834.65M2.62B4.41B3.84B9.86B29.06B57.54B11.29B11.30B8.61B
Gross Profit255.62M821.14M1.03B6.74M31.49B48.14B43.86B-4.15B-1.21B811.11M
Gross Margin23.45%23.87%18.98%0.18%76.16%62.36%43.26%-58.25%-11.96%8.61%
Operating Expense1.89B8.33B5.64B7.08B1.91B13.33B18.89B19.86B24.19B19.63B
Operating Income-1.63B-7.51B-4.60B-7.07B29.58B34.82B24.97B-24.02B-25.39B-18.82B
Operating Margin-149.95%-218.32%-84.48%-183.85%71.54%45.10%24.63%-336.77%-251.49%-199.86%
EBITDA------38.08B-12.12B-15.43B-19.54B
EBITDA Margin------37.55%-169.87%-152.81%-207.51%
Net Income-1.56B-20.96B-40.92B-9.56B-41.02B36.15B26.72B-17.24B-15.19B-23.31B
Net Income Margin-142.94%-609.32%-750.91%-248.66%-99.19%46.83%26.35%-241.69%-150.47%-247.58%
R&D---2.94B3.39B3.92B5.16B3.62B4.63B4.43B
R&D as % of Total Revenue---76.48%8.19%5.07%5.08%50.76%45.84%47.05%
Interest Expense000646.88M579.68M1.64B2.14B1.82B501.25M638.00M
Interest Expense % of Total Revenue0.00%0.00%0.00%16.82%1.40%2.13%2.11%25.56%4.96%6.78%

Balance Sheet

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets18.28B24.37B45.42B72.46B155.56B173.30B133.19B107.64B98.21B
Total Liabilities51.09B8.92B21.11B9.35B54.85B32.72B20.73B10.51B21.67B
Total Equity-32.81B15.46B24.31B63.11B100.71B140.58B112.39B97.13B76.31B
Cash1.97B1.14B21.79B21.89B66.10B52.07B22.26B10.57B19.86B
Total Debt22.73B6.00B3.43B3.21B-----
Net Debt--5.98B------

Cash Flow

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-909.59M-3.13B-4.01B14.57B38.96B30.43B-12.15B-7.52B-14.65B
Investing Cash Flow-11.89B-7.02B-21.24B-639.83M-25.83B-41.94B1.99B6.38B-
Financing Cash Flow14.52B9.32B26.75B683.29M35.94B-2.20B-19.44B-10.71B-
Capital Expenditure211.28M1.85B1.86B4.39B5.27B16.00B5.74B1.95B392.19M
Free Cash Flow--5.88B9.90B33.69B14.43B-17.98B-9.47B-15.04B
Dividends Paid------2.48B0-
FCF to OCF---146.64%67.91%86.47%47.41%147.95%125.96%102.68%
Dividend Paid to FCF-------13.82%0.00%-

Earnings

Report DateJun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------------------
EPS Actual-144.99-131.08-378.48-155.62-1067.42-2006.44214.69357.43-36.64959.97703.512105.55652.73147.16-1527.74-291.15-142.89-401.56-402.49-259.62114.16-284.35-567.09-203.32-343.43-246.93-731.17-278.88-247.60
Surprise-----------------------------
Timing-----------------------------

Key Statistics & Ratios

Market Cap70.18B
Enterprise Value55.89B
Trailing P/E0.00
Forward P/E0.00
Price / Sales7.17
Price / Book1.02
Revenue (TTM)9.78B
Gross Profit (TTM)1.11B
EBITDA-17.00B
Profit Margin-235.12%
Operating Margin-137.03%
Return on Equity-29.06%
Return on Assets-12.63%
Shares Outstanding15.29M
Shares Float12.77M
Beta0.60
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
150.00Dec 27, 2023
20221×
150.00Dec 28, 2022